RxDoctor Payments DataLook up a doctor →

James Lin, DO

Geriatric Medicine · Erie, PANPI 1164599155

Payments from drug & device makers

$72,963in general payments, 2019–2025

Across 362 payments — averaging $201.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Reapplix Inc.$32K
  • Organogenesis Inc.$29K
  • Merz North America, Inc.$4K
  • Boston Scientific$1K
  • Medtronic$750
  • Galderma Laboratories, L.p.$691
  • plus $4K from 50 others

What the payments were for

  • Consulting fees$5,7508%
  • Speaking & faculty fees$53,10273%
  • Travel & lodging$4,1416%
  • Food & beverage$9,85013%
  • Education$1200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,963 in reported general payments places this provider in the 95th percentile of 217 geriatric medicine providers in Pennsylvania.

See all geriatric medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,261,605
Medicare patients
331
Services billed
3,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban324$184,634
XifaxanRifaximin28$85,301
XareltoRivaroxaban129$72,934
OzempicSemaglutide67$66,856
JardianceEmpagliflozin78$50,067
ArexvyRsvpref3 Antigen/As01e/Pf135$39,685
TrulicityDulaglutide33$34,127
Breo ElliptaFluticasone/Vilanterol80$33,758
RexultiBrexpiprazole27$30,922
EntrestoSacubitril/Valsartan48$29,560
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$29,116
TradjentaLinagliptin23$17,573
JanuviaSitagliptin Phosphate31$16,510
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$15,559
MyrbetriqMirabegron32$15,372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$253$184,634324 claims
GSKArexvy, Breo Ellipta, Trelegy Ellipta, Anoro Ellipta, Incruse Ellipta$35$125,131310 claims
Johnson & JohnsonXarelto$181$72,934129 claims
Novo NordiskOzempic$346$66,85667 claims
Lilly USA, LLCTrulicity$322$34,12733 claims
Otsuka America Pharmaceutical, Inc.Rexulti$53$30,92227 claims
NovartisEntresto$203$29,56048 claims
MerckJanuvia, Lagevrio (Eua)$63$28,40443 claims
Astellas Pharma US IncMyrbetriq$97$15,37232 claims
AbbVieTeflaro$104$12,09726 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$23$6,813539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 217 geriatric medicine providers in Pennsylvania.

Other geriatric medicine in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →